ISRCTN72642831已完成不适用
Immunogenicity and safety in children 1 - 9 years of a vaccine against meningococcal serogroup C strain 2135 produced with tetanus toxoid conjugate
The Immunobiological Technology Institute (Bio-Manguinhos) (Brazil)0 个研究点目标入组 360 人开始时间: 2011年3月10日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 360
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Have 12 months of age less than 10 years and have not yet been vaccinated against meningitis C or B (Va-Mengoc.BC®)
- •2. Be accompanied by a parent or other custodian to confirm the ability and willingness to return to the clinic on the dates for the second and third visits
- •3. Be accompanied by a parent or other legal guardian who can provide the information necessary for the research team contact during follow-up
- •4. Be accompanied by a parent or other responsible person legally qualified to give informed consent to participate
- •5. Be users or siblings of children enrolled, in the health unit for routine immunisation or other medical care
- •6. Keep up with routine vaccines officially recommended for the first year of life in Brazil, except meningitis C vaccine and any type of flu shot within the 28 days preceding the vaccination study
- •7. Having good health, according to medical history, physical examination (documented as FRC) and review of the research team
- •8. Are not participating in any other clinical study
排除标准
- •Not to be included, children whose legal guardians:
- •1. Cannot or do not wish to give their informed consent to participate
- •2. Cannot be contacted by phone (the phone itself or the house or neighbour) by the research team for monitoring adverse events and/or in the event of non-attendance at the second and third visits
- •3. Unable to complete the log of adverse events, measure and record the child's temperature, measure the largest diameter of any adverse reactions at the injection site, or read and understand instructions or have other difficulties, according to the research team, justify the exclusion from the study
- •4. Are participating in another clinical study
- •Also not included are children who:
- •5. Have received another vaccine injections 30 days before the day of vaccination study or shall take such vaccines within 30 days after vaccination in the study. Vaccines programmed and not received before inclusion in this study can be administered after the last blood collection.
- •6. Have taken at least one dose of vaccine against meningitis C or BC (Cuban vaccine) in the past
- •7. Have received vaccinations, allergy-free injection in the last 14 days
- •8. Have had any type of meningitis
- •9. Have been treated with antibiotics in the last 10 days
- •10. Have been treated with benzathine penicillin in the last 30 days
- •11. Have fever on the first visit (greater than 37.5°C in the armpit) or 3 days earlier
- •12. Suffering from chronic disease
- •13. Had acute illness in the last 30 days
- •14. Have a history of anaphylaxis, asthma, urticaria or other allergic reaction to previous vaccinations or who have an allergy or hypersensitivity to vaccine components of the study
- •15. Have a history of severe asthma hospitalisation
- •16. Are receiving systemic therapy with high doses of steroids (e.g., 1 mg/kg/day of prednisone or equivalent), or have chronic use of inhaled corticosteroids, high power (e.g., 800 mg per day of fluticasone)
- •17. Have a diagnosed disorder haemophilia or any other disorder associated with prolonged bleeding
- •18. Have sickle cell anaemia
- •19. Have undergone splenectomy
- •20. Have a history of epilepsy, seizures or neurodevelopmental disorders such as autism
- •21. Have received blood, blood products or immunoglobulin preparations intravenously
- •22. Have any disorder, in the opinion of the investigator, may interfere with the evaluation of the objectives of the study
研究者
相似试验
已完成
不适用
Immune Persistence and Safety Pediatric Survey (Aged 5-11 Years) related to the SARS-CoV-2 Vaccination (Primary series and Booster Vaccination) in JapaCOVID-19JPRN-UMIN000047368Juntendo University411
已完成
Unknown
Immune Persistence and Safety Young Children Survey (Aged 6 months - 4 Years) related to the SARS-CoV-2 Vaccination (Initial and Booster Vaccination) in JapaCOVID-19JPRN-UMIN000049534Juntendo University41
已完成
3 期
Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 10 Weeks of AgeInfections, StreptococcalStreptococcus PneumoniaeNCT00814710GlaxoSmithKline360
招募中
不适用
Immune cell profiles in the blood in children, adolescents and adults with tuberous sclerosis complex disease and their correlation with organ manifestations and treatment response to immunotherapy with mTOR inhibitorsQ85.1G40Tuberous sclerosisEpilepsyDRKS00022991niversitätsklinikum Münster90
已完成
3 期
Primary Vaccination Course in Children Receiving the Pneumococcal Vaccine GSK 1024850A, Zilbrix™ Hib and Polio Sabin™Infections, StreptococcalNCT00678301GlaxoSmithKline365